CMS Seeks List Of "Authorized" Generics For Use In "Best Price" Reporting, GPhA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Generic Pharmaceutical Association anticipates the National Governors Association's updated Medicaid recommendations will endorse the inclusion of authorized generics in Medicaid "best price" reporting. CMS has indicated it will consider adding authorized generics to its calculations.
You may also be interested in...
Congressional "Best Price" Proposals Could Eradicate "Authorized" Generic Firms
Pfizer generic subsidiary head Kennally says provision in pending legislation "will likely be overturned."
Congressional "Best Price" Proposals Could Eradicate "Authorized" Generic Firms
Pfizer generic subsidiary head Kennally says provision in pending legislation "will likely be overturned."
"Authorized" Generics Will Be Subject To "Best Price" Calculations, CMS Suggests
Letter to GPhA from agency says that the products are considered innovator multiple source drugs, which would discourage the use of the practice by brand firms. CMS says it is reviewing its policy on calculation of prices for such products.